Analysts expect 20/20 Biolabs, Inc. to report revenue of 914,878.80 for Q3 26, against a range of 876,974.46 to 952,783.14. The most recent reported quarter, Q2 26, came in at 730,570.00, a 10.7% beat against the 659,780.04 consensus.
| Metric | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 538,000.00 | 353,380.00 | 730,570.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | - | 842,863.02 | 708,318.74 | 952,783.14 | 1.13 M | 768,073.73 | 1.40 M | 1.88 M | 2.07 M | 1.26 M | 2.31 M | ||||||||||
| Low Estimate | - | 757,343.20 | 611,241.34 | 876,974.46 | 936,900.28 | 635,013.37 | 1.22 M | 1.70 M | 1.80 M | 1.08 M | 2.15 M | ||||||||||
| Consensus Estimate | - | 800,103.11 | 659,780.04 | 914,878.80 | 1.04 M | 701,543.55 | 1.31 M | 1.79 M | 1.94 M | 1.17 M | 2.23 M |
Analysts expect 20/20 Biolabs, Inc. to report earnings per share of -0.06 for Q3 26, against a range of -0.06 to -0.06. The most recent reported quarter, Q2 26, came in at -0.26, a 136.4% miss against the -0.11 consensus.
| Metric | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.25 | -0.28 | -0.26 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | - | -0.09 | -0.10 | -0.06 | -0.07 | -0.18 | -0.20 | -0.01 | 0.01 | -0.17 | -0.20 | ||||||||||
| Low Estimate | - | -0.11 | -0.12 | -0.06 | -0.07 | -0.20 | -0.22 | -0.01 | 0.01 | -0.19 | -0.22 | ||||||||||
| Consensus Estimate | - | -0.10 | -0.11 | -0.06 | -0.07 | -0.19 | -0.21 | -0.01 | 0.01 | -0.18 | -0.21 |